In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers

Sandhya Vasan, Arlene Hurley, Sarah J Schlesinger, Drew Hannaman, David F Gardiner, Daniel P Dugin, Mar Boente-Carrera, Roselle Vittorino, Marina Caskey, Johanne Andersen, Yaoxing Huang, Josephine H Cox, Tony Tarragona-Fiol, Dilbinder K Gill, Hannah Cheeseman, Lorna Clark, Len Dally, Carol Smith, Claudia Schmidt, Harriet H Park, Jakub T Kopycinski, Jill Gilmour, Patricia Fast, Robert Bernard, David D Ho, Sandhya Vasan, Arlene Hurley, Sarah J Schlesinger, Drew Hannaman, David F Gardiner, Daniel P Dugin, Mar Boente-Carrera, Roselle Vittorino, Marina Caskey, Johanne Andersen, Yaoxing Huang, Josephine H Cox, Tony Tarragona-Fiol, Dilbinder K Gill, Hannah Cheeseman, Lorna Clark, Len Dally, Carol Smith, Claudia Schmidt, Harriet H Park, Jakub T Kopycinski, Jill Gilmour, Patricia Fast, Robert Bernard, David D Ho

Abstract

Background: DNA-based vaccines have been safe but weakly immunogenic in humans to date.

Methods and findings: We sought to determine the safety, tolerability, and immunogenicity of ADVAX, a multigenic HIV-1 DNA vaccine candidate, injected intramuscularly by in vivo electroporation (EP) in a Phase-1, double-blind, randomized placebo-controlled trial in healthy volunteers. Eight volunteers each received 0.2 mg, 1 mg, or 4 mg ADVAX or saline placebo via EP, or 4 mg ADVAX via standard intramuscular injection at weeks 0 and 8. A third vaccination was administered to eleven volunteers at week 36. EP was safe, well-tolerated and considered acceptable for a prophylactic vaccine. EP delivery of ADVAX increased the magnitude of HIV-1-specific cell mediated immunity by up to 70-fold over IM injection, as measured by gamma interferon ELISpot. The number of antigens to which the response was detected improved with EP and increasing dosage. Intracellular cytokine staining analysis of ELISpot responders revealed both CD4+ and CD8+ T cell responses, with co-secretion of multiple cytokines.

Conclusions: This is the first demonstration in healthy volunteers that EP is safe, tolerable, and effective in improving the magnitude, breadth and durability of cellular immune responses to a DNA vaccine candidate.

Trial registration: ClinicalTrials.gov NCT00545987.

Conflict of interest statement

Competing Interests: D. Hannaman and R. Bernard are employees of Ichor Medical Systems, Inc, manufacturer of the TriGridTM device. These authors had a direct role in study design, data collection and analysis, decision to publish, and preparation of the manuscript. Len Dally and Carol Smith are employed by The EMMES Corporation. All other authors have no competing financial interests. The competeing interests of Ichor Medical Systems and the EMMES Corporation do not alter the authors' adherance to all PLoS ONE policies on sharing data and materials.

Figures

Figure 1. Participant Flow Diagram.
Figure 1. Participant Flow Diagram.
Figure 2. Tolerability and Acceptability of Electroporation.
Figure 2. Tolerability and Acceptability of Electroporation.
Volunteers randomized to receive ADVAX or placebo via EP completed a questionnaire to rate the tolerability of the procedure on a 5 point pain scale at three different time points during and after EP (Panel A), and the acceptability of the procedure for future vaccination (Panel B). Results represent a total of 75 responses from 32 volunteers.
Figure 3. Cellular Immune Response.
Figure 3. Cellular Immune Response.
Panel A depicts the fold increase over the HD-IM response in the mean of all IFNγ ELISpot responses to each antigen at Week 10, coinciding with the peak cellular immune response. Panel B depicts the sum of all mean ELISpot counts for each peptide pool at each study time point for all ADVAX dose groups, color coded by antigen. SFU  =  spot forming units.
Figure 4. Individual IFNγ ELISpot Responses.
Figure 4. Individual IFNγ ELISpot Responses.
All individual background-subtracted IFNγ ELISpot counts to each antigen at study Week 10, the peak response after the second administration. Horizontal lines indicate median values for each group. P-values indicate pair-wise comparisons of the three EP responses with HD-IM responses using the non-parametric Wilcoxon 2-sample test (t approximation). Significance is set at p

References

    1. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 1993;259:1745–1749.
    1. Donnelly JJ, Wahren B, Liu MA. DNA vaccines: progress and challenges. J Immunol. 2005;175(2):633–639.
    1. Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer. 2008;8:108–120.
    1. Wang R, Doolan DL, Le TP, Hedstrom RC, Coonan KM, et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science. 1998;282:476–480.
    1. Rottinghaus ST, Poland GA, Jacobson RM, Barr LJ, Roy MJ. epatitis DNA vaccine induces protective antibody responses in human nonresponders to conventional vaccination. Vaccine. 2003;21:4604–4608.
    1. Catanzaro AT, Roederer M, Koup RA, Bailer RT, Enama ME, et al. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine. 2007;25:4085–4092.
    1. Graham BS, Koup RA, Roederer M, Bailer RT, Enama ME, et al. Phase I Safety and Immunogenicity Evaluation of a Multiclade HIV-1 Candidate DNA Vaccine. J Infect Dis. 2006;194:1650–1660.
    1. Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet. 2008;9:776–788.
    1. McConkey SJ, Reece WH, Moorthy VS, Webster D, Dunachie S, et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med. 2003;9:729–735.
    1. Harari A, Bart PA, Stöhr W, Tapia G, Garcia M, et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med. 2008;205:63–77.
    1. Jaoko W, Nakwagala FN, Anzala O, Manyonyi GO, Birungi J, et al. Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine. 2008;26:2788–2795.
    1. Goonetilleke N, Moore S, Dally L, Winstone N, Cebere I, et al. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. Virol. 2006;80:4717–4728.
    1. Wang S, Kennedy JS, West K, Montefiori DC, Coley S, et al. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine. 2008;26:3947–3957.
    1. Nwanegbo E, Vardas E, Gao W, Whittle H, Sun H, et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol. 2004;11:351–357.
    1. Mast TC, Kierstead L, Gupta SB, Nikas AA, Kallas EG, et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine. 2009;28:950–957.
    1. Santra S, Seaman MS, Xu L, Barouch DH, Lord CI. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J Virol. 2005;79:6516–6522.
    1. Schalk JA, Mooi FR, Berbers GA, van Aerts LA, Ovelgönne H, et al. Preclinical and clinical safety studies on DNA vaccines. Hum Vaccin. 2006;2:45–53.
    1. Manam S, Ledwith BJ, Barnum AB, Troilo PJ, Pauley CJ. Plasmid DNA vaccines: tissue distribution and effects of DNA sequence, adjuvants and delivery method on integration into host DNA. Intervirology. 2000;43:273–281.
    1. Mathiesen I. Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene Ther. 1999;6:508–14.
    1. Widera G, Austin M, Rabussay D, Goldbeck C, Barnett SW, et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol. 2000;164:4635–40.
    1. Babiuk S, Baca-Estrada ME, Foldvari M, Middleton DM, Rabussay D, et al. Increased gene expression and inflammatory cell infiltration caused by electroporation are both important for improving the efficacy of DNA vaccines. J Biotechnol. 2004;110:1–10.
    1. Liu J, Kjeken R, Mathiesen I, Barouch DH. Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation. J Virol. 2008;82:5643–5649.
    1. Babiuk S, Baca-Estrada ME, Foldvari M, Storms M, Rabussay D et al. Electroporation improves the efficacy of DNA vaccines in large animals. Vaccine. 2002;20:3399–3408.
    1. Luxembourg A, Hannaman D, Ellefsen B, Nakamura G, Bernard R. Enhancement of immune responses to an HBV DNA vaccine by electroporation. Vaccine. 2006;24:4490–4493.
    1. Li Z, Zhang H, Fan X, Zhang Y, Huang J, et al. DNA electroporation prime and protein boost strategy enhances humoral immunity of tuberculosis DNA vaccines in mice and non-human primates. Vaccine. 2006;24:4565–4568.
    1. Hooper JW, Golden JW, Ferro AM, King AD. Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge. Vaccine. 2007;25:1814–1823.
    1. Luckay A, Sidhu MK, Kjeken R, Megati S, Chong SY, et al. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J Virol. 2007;81:5257–5269.
    1. Dobaño C, Widera G, Rabussay D, Doolan DL. Enhancement of antibody and cellular immune responses to malaria DNA vaccines by in vivo electroporation. Vaccine. 2007;25:6635–6645.
    1. Hirao LA, Wu L, Khan AS, Hokey DA, Yan J, et al. Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine. 2008;26:3112–3120.
    1. Livingston BD, Little SF, Luxembourg A, Ellefsen B, Hannaman D. Comparative performance of a licensed anthrax vaccine versus electroporation based delivery of a PA encoding DNA vaccine in rhesus macaques. Vaccine. 2010;28(4):1056–1061.
    1. Rosati M, Valentin A, Jalah R, Patel V, von Gegerfelt A, et al. Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation. Vaccine. 2008;26(40):5223–5229.
    1. Chen MW, Cheng TJ, Huang Y, Jan JT, Ma SH, Yu AL, et al. A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc Natl Acad Sci U SA. 2008;105:13538–13543.
    1. Sersa G, Miklavcic D, Cemazar M, Rudolf Z, Pucihar G, Snoj M. Electrochemotherapy in treatment of tumours. Eur J Surg Oncol. 2008;34:232–240.
    1. Stevenson FK, Ottensmeier CH, Johnson P, Zhu D, Buchan SL, et al. DNA vaccines to attack cancer. Proc Natl Acad Sci U S A. 2004;101(Suppl 2):14646–14652.
    1. Low L, Mander A, McCann K, Dearnaley D, Tjelle T, et al. DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum Gene Ther. 2009;20:1269–1278.
    1. Huang Y, Chen Z, Zhang W, Gurner D, Song Y, et al. Design, construction, and characterization of a dual-promoter multigenic DNA vaccine directed against an HIV-1 subtype C/B' recombinant. J Acquir Immune Defic Syndr. 2008;47:403–411.
    1. Vasan S, Schlesinger SJ, Huang Y, Hurley A, Lombardo A, et al. Phase 1 Safety and Immunogenicity Evaluation of ADVAX, a Multigenic, DNA-based Clade C/B' HIV-1 Candidate Vaccine. PLOS One. 2010;5(1):e8617, p1–7.
    1. McCormack S, Stöhr W, Barber T, Bart PA, Harari A, et al. EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine. 2008;26:3162–3174.
    1. Chong SY, Egan MA, Kutzler MA, Megati S, Masood A, et al. Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV89.6P challenge in rhesus macaques. Vaccine. 2007;25:4967–4982.
    1. Weiskopf D, Weinberger B, Grubeck-Loebenstein B. The aging of the immune system. Transpl Int. 2009;22:1041–1050.
    1. Asmuth DM, Brown EL, DiNubile MJ, Sun X, del Rio C, et al. Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens. J Infect Dis. 2010;201:132–141.
    1. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T-cells. Blood. 2006;107:4781–4789.
    1. Letvin NL, Mascola JR, Sun Y, Gorgone DA, Buzby AP, et al. Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science. 2006;312:1530–1533.
    1. Vasan S, Schlesinger SJ, Arrode G. T-Cell Immune Responses to HIV-1. Front Biosci. 2007;12:2330–2343.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する